A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT01981122
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Prostate Cancer
Interventions
BIOLOGICAL:
sipuleucel-T
DRUG:
enzalutamide
Sponsor
Dendreon